The 8th Annual Summit on Controlled Substances – Regulation, Litigation, and Enforcement examines the evolving legal and regulatory environment affecting organizations across the controlled substances supply chain.

As DEA and DOJ enforcement priorities evolve, pharmaceutical manufacturers, distributors, pharmacies, healthcare providers, and prescribers face growing challenges involving diversion prevention, suspicious-order monitoring, prescription validity, telemedicine requirements, production quotas, and regulatory compliance.

The summit brings together industry leaders, government officials, legal practitioners, and compliance executives to share practical strategies, examine enforcement trends, and prepare for emerging legal and operational risks.

Key Topics

• DEA and DOJ enforcement priorities
• Controlled Substances Act enforcement across federal and state frameworks
• Diversion prevention and suspicious-order monitoring
• Telemedicine prescribing and DEA Special Registration developments
• Pharmaceutical quotas, supply continuity, and patient access
• Healthcare fraud, dispensing liability, and prescription validity
• Marijuana rescheduling, hemp-derived cannabinoids, psychedelics, kratom, and emerging substances
• AI, data analytics, ARCOS intelligence, and compliance monitoring
• Drug supply chain compliance and DSCSA implementation
• Federal and state regulatory developments

Conference Co-Chairs

• Jolie Apicella — Partner, Wiggin and Dana, LLP
• Gus Eyler — Partner, Gibson, Dunn & Crutcher LLP
• Cori L. Rizman — Vice President of DEA Compliance, Ascent Pharmaceuticals, Inc.

Featured Government and Industry Speakers
The supplied event information lists speakers and representatives from the U.S. Department of Justice, the White House Office of National Drug Control Policy, the U.S. Food and Drug Administration, Johnson & Johnson Innovative Medicine, McKesson, Guidepost Solutions, UT Southwestern Medical Center, Talkiatry, and Angels for Change.

Continuing Legal Education: CLE credits are available; jurisdictions and credit amounts should be confirmed with the organizer.

Additional Pre-Conference Workshop:
The Life Sciences Enforcement Operations LAB takes place February 3, 2027, from 10:00 AM to 4:00 PM. This limited-seat, scenario-driven workshop focuses on managing the first 72 hours of FDA, DEA, DOJ, and state enforcement scrutiny. It is a separate pre-conference program.

Main Conference Dates: February 4–5, 2027
Venue: District of Columbia Bar, Washington, DC
Organizer: American Conference Institute (ACI), part of C5 Group